Your browser doesn't support javascript.
loading
Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis.
Zimmerman, Brittney S; Seidman, Danielle; Cascetta, Krystal P; Ru, Meng; Moshier, Erin; Tiersten, Amy.
Afiliação
  • Zimmerman BS; Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA, brittney.zimmerman@mountsinai.org.
  • Seidman D; Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Cascetta KP; Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Ru M; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Moshier E; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Tiersten A; Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Oncology ; 99(5): 280-291, 2021.
Article em En | MEDLINE | ID: mdl-33652435
ABSTRACT

INTRODUCTION:

The aim of this study was to assess for clinicopathologic and socioeconomic features that predict improved survival for patients with advanced breast cancer with synchronous brain metastases at diagnosis.

METHODS:

We utilized the National Cancer Database (NCDB) to identify all patients with brain metastases present at diagnosis, with adequate information on receptor status (ER, PR, Her2), clinical T stage of cT1-4, clinical M1, with 3,943 patients available for analysis. The association between brain metastases patterns and patient/disease variables was examined by robust Poisson regression model. Cox proportional hazards model was used to quantify the associations between overall survival (OS) and these variables.

RESULTS:

In univariable analysis, OS was significantly associated with the number of sites of metastases (p < 0.0001). Patients with 2 or more additional extracranial sites of metastases had significantly worse OS (median 8.8 months, 95% confidence interval [CI] 7.8, 9.9) than patients with brain metastases only (median OS 10.6 months, 95% CI 9.4, 12.9) or brain metastases plus one other extracranial site of metastases (median OS 13.1 months, 95% CI 11.8, 14.4). Risk factors which predicted poor prognosis included triple-negative disease, high comorbidity score, poorly differentiated tumors, invasive lobular histology, multi-organ involvement of metastases, and government or lack of insurance. Factors which improve survival include younger age and Hispanic race. DISCUSSION/

CONCLUSION:

Using a large NCDB, we identified various factors associated with prognosis for patients with brain metastases at the time of breast cancer diagnosis. Insurance status and related socioeconomic challenges provide potential areas for improvement in care for these patients. This information may help stratify patients into prognostic categories at the time of diagnosis to improve treatment plans.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias da Mama / Bases de Dados Factuais / Carcinoma Lobular / Carcinoma Ductal de Mama Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias da Mama / Bases de Dados Factuais / Carcinoma Lobular / Carcinoma Ductal de Mama Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article